| H-1PV | Parvovirus H-1 |
| h5G1.1 | Eculizumab |
| HAART | Combination antiretroviral therapy; Highly active antiretroviral therapy |
| hADM | Human acellular dermal matrix |
| HAL | Hexaminolevulinate |
| HAP TH-302 | Evofosfamide |
| HAR | alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine |
| hATG | Horse anti-thymocyte globulin |
| HB1.F3.CD neural stem cells | E. coli CD-expressing genetically modified neural stem cells |
| HBV | Hepatitis B virus |
| HC | Therapeutic hydrocortisone |
| HCA | Heterocyclic amine |
| HCC | Hepatocellular carcinoma |
| HCD20 | hA20; Veltuzumab |
| hCE1m6-NSC | Carboxylesterase-expressing allogeneic neural stem cells |
| HCIG | Hepatitis C immune globulin intravenous |
| HCQ | Hydroxychloroquine |
| hCRF | Human corticotropin-releasing factor |
| HCT | Hematocrit |
| HCV | Hepatitis C virus |
| HDAC | Histone deacetylase |
| HDC | Hydrocortisone sodium succinate |
| HDGC | Familial diffuse gastric cancer; Hereditary diffuse gastric cancer |
| HDPC | Miltefosine |
| HDR | High-dose radiation |
| HE4 | Human epididymis protein 4 |
| HER1 | Epidermal growth factor receptor |
| HER-2 | HER-2/neu peptide vaccine |
| HER2 | c-erbB-2; Human EGF receptor 2; Human epidermal growth factor receptor 2 |
| HER2Bi-armed ATCs | HER2Bi-armed activated T cells |
| HER2/neu | c-erbB-2; Human EGF receptor 2; Human epidermal growth factor receptor 2 |
| HES | Hetastarch |
| hetIL-15 | Heterodimeric interleukin-15 |
| HFTP | Absorbable fibrin sealant patch |
| HGS-ETR1 | anti-TRAIL R1-mAb; Mapatumumab |
| HGS-ETR2 | anti-TRAIL R2 mAb HGS-ETR2; Lexatumumab |
| HGWWD | Huangqi Guizhi Wuwu decoction |
| HHS | Department of Health and Human Services |
| HHT | Omacetaxine mepesuccinate |
| HHV | Herpes simplex virus; Human herpesvirus |
| HHV8 | Human herpesvirus 8; Kaposi sarcoma-associated herpesvirus |
| HIF | Hypoxia-inducible factor |
| HIFU | High-intensity focused ultrasound therapy |
| HIPAA | Health Insurance Portability and Accountability Act; Kassebaum Kennedy Act |
| HIPEC | Continuous hyperthermic peritoneal perfusion; Hyperthermic intraperitoneal chemotherapy |
| HIV | Human immunodeficiency virus |
| HLA | Human leukocyte antigen; Human lymphocyte antigen |
| HLA-A2A3-FGF5-ISA51 | HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine |
| hLF(1-11) | Human lactoferrin peptide hLF1-11 |
| HLH | Hemophagocytic lymphohistiocytosis |
| hLL1 | Milatuzumab |
| hLL2 | Epratuzumab |
| HLRCC | Hereditary leiomyomatosis and renal cell cancer |
| HMAF | Irofulven |
| HMB supplement | Beta-hydroxy-beta-methylbutyrate supplement |
| HMBA | Hexamethylene bisacetamide |
| HMM | Altretamine |
| hMPC CLT-008 | Human myeloid progenitor cells CLT-008 |
| HNPCC | Hereditary nonpolyposis colorectal cancer; Lynch syndrome |
| HP 129Xe | Hyperpolarized xenon 129 |
| HP3He | Hyperpolarized helium 3 |
| HPA-23 | Antimoniotungstate |
| HPD | Hematoporphyrin derivative |
| HPGF | Recombinant interleukin-6 |
| HPRC | Hereditary papillary renal cancer; Hereditary papillary renal carcinoma |
| HPV | Human papillomavirus |
| HPV 16/18 L1 VLP/AS04 VAC | Recombinant human papillomavirus bivalent vaccine |
| HPV16-E6-T27 | HPV16-targeting TALEN T27 |
| HPV16-E7-T512 | HPV16-targeting TALEN T512 |
| HRT | Hormone replacement therapy |
| HRW | Hydrogen-rich water |
| HSCAS | Hydrated sodium calcium aluminosilicate |
| HSIL | High-grade squamous intraepithelial lesion |
| HSP | Heat-shock protein; Stress protein |
| HSP70 | Recombinant 70-kD heat-shock protein |
| HSPC | Androgen-dependent prostate cancer; Androgen-sensitive prostate cancer; Castrate-sensitive prostate cancer; Hormone-sensitive prostate cancer |
| HspE7 | HPV 16 E7/HSP65 Vaccine; HPV E7 Peptide Epitope Vaccine |
| HSV | Herpes simplex virus; Human herpesvirus |
| hTFF1-secreting Lactococcus lactis AG013 | Human trefoil factor 1-secreting Lactococcus lactis AG013 |
| HTLV-1 | Human T-cell leukemia virus type 1; Human T-cell lymphotropic virus type 1 |
| HTS | Hypertonic saline |
| HU | Hydroxyurea |
| hu14.18-IL2 | hu14.18-IL2 fusion protein |
| Hu3F8Bi-armed ATC | anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes |
| hu3F8-BsAb | Nivatrotamab |
| huC242-DM4 | Maytansinoid DM4-conjugated humanized monoclonal antibody huC242 |
| huDs6-DM4 | anti-CA6-DM4 immunoconjugate SAR566658 |
| HuFR-1 | Multi-epitope folate receptor alpha peptide vaccine |
| HuHMFG1 | Sontuzumab |
| human PSMA DNA | Human prostate-specific membrane antigen plasmid DNA vaccine |
| HuMax-AXL-ADC | anti-AXL monoclonal antibody-MMAE conjugate |
| HuMax-CD20 | Arzerra; Ofatumumab |
| HYC | Hycanthone |
| HyperCVAD | HyperCVAD regimen |